A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
NCT ID: NCT04104997
Last Updated: 2020-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
39 participants
INTERVENTIONAL
2019-09-26
2020-07-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
The A group in 5% GLH8NDE
Three times administration both eyes, each 1 drop in Korean
5% GLH8NDE
5% GLH8NDE as eye drops
The A group in placebo
Three times administration both eyes, each 1 drop in Korean
Placebos
Placebo as eye drops
The B group in 5% GLH8NDE
Six administration both eyes, each 1 drop in Korean
5% GLH8NDE
5% GLH8NDE as eye drops
The B group in placebo
Six administration both eyes, each 1 drop in Korean
Placebos
Placebo as eye drops
The C group in 5% GLH8NDE
Six administration both eyes, each 2 drop in Korean
5% GLH8NDE
5% GLH8NDE as eye drops
The C group in placebo
Six administration both eyes, each 2 drop in Korean
Placebos
Placebo as eye drops
The D group in 5% GLH8NDE
Six administration both eyes, each 2 drop in Caucasian
5% GLH8NDE
5% GLH8NDE as eye drops
The D group in placebo
Six administration both eyes, each 2 drop in Caucasian
Placebos
Placebo as eye drops
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5% GLH8NDE
5% GLH8NDE as eye drops
Placebos
Placebo as eye drops
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject who has body weight between 55.0 and 90.0 kg, and BMI between 18.0 and 27.0
* Subject who signed and dated the informed consent form after understanding fully to hear a detailed explanation in the clinical trial
Exclusion Criteria
* A subject who has a history of disease with myocardial infarction, stroke, arrhythmia, hypotension (90 mmHg amine or diastolic blood pressure less than 50 mmHg at screening), uncontrolled hypertension (greater than 170 mmHg diastolic blood pressure or 100 mmHg diastolic blood pressure at screening), coronary artery, or who has a current abnormality
* A subject with a history of hypersensitivity to the drug (aspirin, antibiotics, etc.) or clinical significant hypersensitivity reactions
* A subject with the following findings in paperweight, visual acuity test, front eye photo, corneal refraction test, intraocular pressure test, slit lamp microscopy examination, fundus examination, tear break-up time examination, tear secretion test, OSDI (ocular surface disease index) are excluded
1. A subject with suspected history or symptoms of visual organs, including keratitis, uveitis, retinitis, dry eye and strabismus
2. A subject who has had eye surgery (including those who have received more than 6 months for eye laser surgery)
3. A subject at least one eye with an intra-ocular pressure of 22 mmHg or more at the screening
4. At the screening, tear break-up time of at least one eye in both eyes is less than 10 seconds and diagnosed as dry eye according to OSDI test
5. A subject whose ratio for at least one eye in both eyes during screening is less than 10 mm as measured for 5 minutes in an Un-anesthetized Schirmer's test
6. There are side effects to people who wear contact lenses after wearing them or within a month
* A subject with a history of drug abuse or a positive urine drug screening for drug abuse
* A subject who has participated in any other clinical trials and bioequivalence had medication within 6 months prior to the first administration of investigational product (The end date of another clinical trial is based on the last day of the administration)
* A subject who has taken any ethical-the-counter drug or herbal drug within 2 weeks has taken any over-the-counter drug or vitamin include artificial tears within 1 week before the investigational product
* A subject who has donated whole blood within 2 months or blood components within 1 month prior to the investigational product administration
* History of regular alcohol consumption exceeding 21 units/week (1 unit = 10 g of pure alcohol) within 60 days before the investigational product or non-stop the alcohol drinking
* The current smoker, but except the subject to quit the smoke over 90 days
* Recognized contraceptive methods (e.g. your and your partner's infertility surgery, your partner's intrauterine device (IUD), cervical caps or contraceptive diaphragms for use with spermicides) Single block), cervical cap or contraceptive diaphragm with male condom (double block)\]
* A subject who have to work that cause excessive eye fatigue during this clinical trial
* A subject who is not eligible for the study due to reasons on the investigators' judgement
20 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GL Pharm Tech Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MinChang Kwon, Ph. D
Role: STUDY_DIRECTOR
GL PharmTech Corp.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GLH8NDE-101
Identifier Type: -
Identifier Source: org_study_id